Bad Breath, Bloating, Brain Fog, Digestive Discomfort, Facial Puffiness, Gastrointestinal Symptoms, Low Energy Levels, Mood Instability, Skin Clarity, Sleep Quality
Conditions
Brief summary
This is a decentralized (fully virtual), single-group, open-label, prospective clinical trial evaluating the effects of Super Liver Liquid Drops, a liquid botanical dietary supplement, on gut health, digestive comfort, energy levels, and overall well-being over 12 weeks. All 35 enrolled participants will self-administer 2 mL of Super Liver Liquid Drops daily (2 droppers filled to 1 mL each) in the morning with breakfast for the full 12-week intervention period. Participants will complete validated questionnaires and self-reported assessments at Baseline, Week 2, Week 4, Week 8, and Week 12 via the Citruslabs study platform. All study activities will be conducted remotely.
Interventions
DIETARY_SUPPLEMENTSuper Liver
All 35 enrolled participants self-administer 2 mL of Super Liver Liquid Drops daily (2 droppers filled to 1 mL each), taken in the morning with breakfast, for 12 consecutive weeks.
Sponsors
SuperBonsai Inc.
Citruslabs
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Be male or female. * Be aged 30-65 years (inclusive) at the time of enrollment. * Over the past four weeks, has had concerns regarding low energy levels and at least two of the following: Bloating, Digestion, Irregular Bowel movements, Brain fog. * Anyone who is generally healthy - does not live with any uncontrolled chronic disease. * Willing and able to follow the study protocol as described. * Willing to maintain their current diet, exercise routine, and sleep patterns, for the duration of the trial. * If taking other over-the-counter supplements or herbal remedies is willing to maintain this routine without introducing any other new products for the study duration. * Resides in the United States. * Willing to follow the study protocol as described.
Exclusion criteria
* Known allergy or sensitivity to any of the study product ingredients (milk thistle, dandelion, yellow dock, turmeric, ginger, chicory/inulin, berberine). * Known history of severe digestive disorders like acid reflux, Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), Crohn's disease, or gastrointestinal tract surgeries. * Known history of gallbladder disease or bile duct obstruction. * Has a chronic health condition that could impact participation in this study, such as oncological or psychiatric disorders. * Has a planned surgery in the next 12 weeks. * Currently pregnant, breastfeeding, or planning to become pregnant during the study period. * Known history of substance abuse. * Currently, or was in the past 3 months, a smoker. * Currently participating in or planning to participate in another research study during the study period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Gastrointestinal Symptom Rating Scale (GSRS) | Baseline to Week 12 | Change from baseline to Week 12 in gastrointestinal symptom severity as assessed by the Gastrointestinal Symptom Rating Scale (GSRS). Higher scores indicate greater gastrointestinal symptom severity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Self-Reported Energy Level Score | Baseline to Week 12 | Change from baseline to Week 12 in participant-reported energy level, as assessed using the study questionnaire. |
| Change in Self-Reported Brain Fog Score | Baseline to Week 12 | Change from baseline to Week 12 in participant-reported brain fog, as assessed using the study questionnaire. |
| Change in Self-Reported Mood Stability Score | Baseline to Week 12 | Change from baseline to Week 12 in participant-reported mood stability, as assessed using the study questionnaire. |
| Change in Self-Reported Sleep Quality Score | Baseline to Week 12 | Change from baseline to Week 12 in participant-reported sleep quality, as assessed using the study questionnaire. |
| Change in Self-Reported Skin Clarity Score | Baseline to Week 12 | Change from baseline to Week 12 in participant-reported skin clarity, as assessed using the study questionnaire. |
| Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) | Continuous monitoring over 12 weeks | Incidence, severity, and relationship to study product of treatment-emergent adverse events occurring from the first dose of study product through the end of the 12-week study period. |
Countries
United States
Outcome results
None listed